Edition:
United States

PDL BioPharma Inc (PDLI.OQ)

PDLI.OQ on NASDAQ Stock Exchange Global Select Market

2.19USD
30 Nov 2016
Change (% chg)

-- (--)
Prev Close
$2.19
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
431,424
52-wk High
$4.02
52-wk Low
$2.51

PDLI.OQ

Chart for PDLI.OQ

About

PDL BioPharma, Inc., formerly Protein Design Labs, Inc., manages a portfolio of patents and royalty assets, consisting of its Queen et al. patents, license agreements with various biotechnology and pharmaceutical companies, and royalty and other assets acquired. The Company provides non-dilutive growth capital and financing... (more)

Overall

Beta: 0.71
Market Cap(Mil.): $501.59
Shares Outstanding(Mil.): 165.54
Dividend: --
Yield (%): --

Financials

  PDLI.OQ Industry Sector
P/E (TTM): 2.86 42.21 29.87
EPS (TTM): 1.06 -- --
ROI: 17.31 -1.09 14.95
ROE: 25.94 -2.39 16.29

BRIEF-PDL BioPharma issues $150.0 mln of 2.75 pct convertible senior notes

* PDL BioPharma issues $150.0 million of 2.75 pct convertible senior notes due 2021 Source text for Eikon: Further company coverage:

Nov 22 2016

BRIEF-PDL BioPharma modifies Direct Flow financing proposal from equity investment to loan - SEC filing

* Company is evaluating its alternatives regarding its investment in Direct Flow Medical in light of modified proposal- SEC filing

Nov 17 2016

BRIEF-PDL Biopharma announces proposed $150 mln public offering of new convertible senior notes due 2021

* Expects to enter into a capped call transaction with royal bank of canada, which is the sole structuring advisor for offering

Nov 15 2016

BRIEF-PDL BioPharma qtrly earnings per share $0.08

* PDL BioPharma announces third quarter 2016 financial results

Nov 03 2016

BRIEF-PDL Biopharma announces conclusion of debt financing agreement with Paradigm Spine

* PDL Biopharma announces the successful conclusion of its debt financing agreement with Paradigm Spine

Aug 29 2016

BRIEF-PDL Biopharma reports Q2 adjusted earnings per share $0.09

* PDL Biopharma announces second quarter 2016 financial results

Aug 04 2016

BRIEF-PDL Biopharma dismisses quarterly cash dividend

* Board of directors has decided to eliminate its quarterly cash dividend Source text for Eikon: Further company coverage:

Aug 04 2016

BRIEF-PDL Biopharma completes second tranche payment under royalty transaction

* PDL Biopharma completes second tranche payment under royalty transaction with Ariad Pharmaceuticals Source text for Eikon: Further company coverage:

Aug 01 2016

BRIEF-PDL Biopharma files for mixed shelf of up to $250 mln

* Files for mixed shelf of up to $250 million - SEC filing Source text - http://1.usa.gov/1UHKNiR Further company coverage:

Jun 10 2016

Earnings vs. Estimates